| Revue: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453201 |
| ISSN: | 0034-8376 |
| Autores: | Atici, Adem1 Rasih Sonsoz, Mehmet2 Ali Barman, Hasan3 Durmaz, Eser4 Demirkiran, Ahmet2 Gulsen, Kamil5 Elitok, Ali2 Onur, Imran2 Sahin, Irfan5 Bilge, Ahmet Kaya2 |
| Instituciones: | 1Istanbul Medeniyet University, Cardiology Departments, Estambul. Turquía 2Istanbul University, Istanbul School of Medicine, Estambul. Turquía 3Okmeydani Training and Research Hospital, Cardiology Departments, Estambul. Turquía 4Istanbul University, Cerrahpasa School of Medicine, Estambul. Turquía 5Bagcilar Training and Research Hospital Istanbul, Cardiology Departments, Estambul. Turquía |
| Año: | 2020 |
| Periodo: | Sep-Oct |
| Volumen: | 72 |
| Número: | 5 |
| Paginación: | 300-307 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Background: Vasovagal syncope (VVS) is a common clinical condition involving genetic background. The role of beta-blockers in the treatment is controversial. Objective: The aim of this study was to investigate the effect of beta-1 gene polymorphism on beta-blocker therapy in patients with VVS. Methods: We included 123 patients who were diagnosed with VVS after the tilt-table test. We searched for the polymorphism Arg389Gly (rs1801253) in the beta-1 adrenoceptor gene. Results: Overall, 64 patients (52%) had Arg389Arg genotype and 59 patients (48%) had Arg389Gly genotype. The syncopal episodes of patients with Arg389Arg genotype were more frequent compared with patients having Arg389Gly genotype (total syncopal episodes [TSE], 7.9 ± 3.7 vs. 6.4 ± 3.0; p = 0.012). TSE in patients with Arg389Arg genotype decreased significantly after 18 months of beta-blocker treatment (7.9 ± 3.7 vs. 3.0 ± 1.4, p < 0.001). After 18 months of beta-blocker treatment, patients with Arg389Arg genotype had significantly fewer syncopal episodes than patients with Arg389Gly genotype (3.0 ± 1.4 vs. 6.8 ± 3.2, p < 0.001). Conclusions: Results of beta-blocker therapy in patients with Arg389Arg genotype suggest that VVS pathophysiology is a multifactorial condition, with genetic, psychological, and environmental components, and therefore, treatment selection can be based on gene polymorphism |
| Disciplinas: | Medicina |
| Palabras clave: | Sistema cardiovascular, Genética, Síncope vasovagal, Polimorfismo genético, Beta bloqueadores |
| Keyword: | Cardiovascular system, Genetics, Genetic polymorphism, Vasovagal syncope, Beta blockers |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
